10 completed. 10 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 10 |
| Phase 2 | 2 | Completed 2 |
Follow Other Solid Tumors: new trials by email Literature Review of Other Solid Tumors trials Research Report on Other Solid Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of CDX-585 in Patients With Advanced Malignancies CDX-585 - Non-small Cell Lung Cancer, Gastric Cancer | Phase 1 | Completed | Celldex Therapeutics | 20 | 2023-05-11 | 2025-06-15 |
| A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD) HC-5404-FU - Renal Cell Carcinoma, Gastric Cancer | Phase 1 | Completed | HiberCell, Inc. | 23 | 2021-06-08 | 2024-03-08 |
| A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies CDX-527 - Non-small Cell Lung Cancer, Breast Cancer | Phase 1 | Completed | Celldex Therapeutics | 27 | 2020-08-04 | 2023-06-18 |
| A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China JAB-3312 - Non-small Cell Lung Cancer, Colorectal Cancer | Phase 1 | Completed | Allist Pharmaceuticals, Inc. | 17 | 2020-07-14 | 2025-05-20 |
| Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment Selinexor 100 mg, Docetaxel, Pembrolizumab - Non-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (CRC) | Phase 1 / Phase 2 | Completed | Karyopharm Therapeutics Inc | 80 | 2020-02-09 | 2026-10-09 |
| A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors JAB-3312 - Non-small Cell Lung Cancer, Colorectal Cancer | Phase 1 | Completed | Jacobio Pharmaceuticals Co., Ltd. | 40 | 2019-09-26 | 2025-12-29 |
| A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies CDX-1140, CDX-301, pembrolizumab - Melanoma, Non-small Cell Lung Cancer | Phase 1 | Completed | Celldex Therapeutics | 132 | 2017-12-01 | 2024-03-28 |
| A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors PF-06801591 - Part 1, MELANOMA | Phase 1 | Completed | Pfizer | 147 | 2016-02-10 | 2021-12-13 |
| Phase I/II Study of PDR001 in Patients With Advanced Malignancies PDR001 - Melanoma, Non-small Sell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 319 | 2015-04-27 | 2022-08-03 |
| A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014) Comparator: MK0752, Notch Inhibitor, Comparator: MK0752, Notch Inhibitor - 450 mg, Comparator: MK0752, Notch Inhibitor - 3 days on, 4 off - Advanced Breast Cancer, Other Solid Tumors | Phase 1 | Completed | Merck Sharp & Dohme LLC | 103 | 2005-04-01 | 2015-01-30 |
Carcinoma, Non-Small-Cell Lung (7) · Breast Neoplasms (5) · Colorectal Neoplasms (5) · Carcinoma, Renal Cell (4) · Stomach Neoplasms (4) · Cholangiocarcinoma (3) · Esophageal Neoplasms (3) · Fallopian Tube Neoplasms (3) · Head and Neck Neoplasms (3) · Liver Neoplasms (3) · Melanoma (3) · Ovarian Neoplasms (3) · Carcinoma, Pancreatic Ductal (2) · Esophageal Squamous Cell Carcinoma (2) · Noonan Syndrome (2)
Neoplasms (9) · Neoplasms by Site (9) · Bronchial Neoplasms (8) · Carcinoma (8) · Carcinoma, Bronchogenic (8) · Lung Diseases (8) · Neoplasms by Histologic Type (8) · Neoplasms, Glandular and Epithelial (8) · Respiratory Tract Diseases (8) · Respiratory Tract Neoplasms (8) · Thoracic Neoplasms (8) · Digestive System Diseases (7) · Digestive System Neoplasms (7) · Gastrointestinal Diseases (7) · Lung Neoplasms (7)
pembrolizumab (2) · Docetaxel (1) · Drug Therapy (1) · IFL protocol (1) · selinexor (1) · spartalizumab (1)
Celldex Therapeutics (3) · Allist Pharmaceuticals, Inc. (1) · HiberCell, Inc. (1) · Jacobio Pharmaceuticals Co., Ltd. (1) · Karyopharm Therapeutics Inc (1) · Merck Sharp & Dohme LLC (1) · Novartis Pharmaceuticals (1) · Pfizer (1)
United States (7) · Poland (2) · Bulgaria (1) · Canada (1) · China (1) · France (1) · Germany (1) · Hungary (1) · Israel (1) · Italy (1) · Lebanon (1) · Malaysia (1) · Netherlands (1) · Norway (1) · Russia (1)
Jose Iglesias, MD (1) · Yuankai Shi, MD (1)
PMID 22547604, PMID 31145415, PMID 32179633, PMID 32364844, PMID 34694529, PMID 39671539
2014 (1), 2016 (1)